R. Yogananda

The goal of the present investigation was to formulate and evaluate chitosan and Eudragit Nanoparticles of Stavudine for antiviral therapy. Nanoparticles of Stavudine were prepared using chitosan, Eudragit S 100, liquid paraffin and Tween-20 using Emulsion droplet coalescence method. The concentration of the polymers Chitosan and Eudragit S 100 were selected based on the results on preliminary screening. The nanoparticles prepared were evaluated for morphology, loading efficiency and in-vitro release. The particle shape and morphology of the prepared Stavudine nanoparticles were determined by SEM analysis. The amount of Stavudine entrapment in the nanoparticles was calculated by the difference between the total amount of drug added to the nanoparticle and the amount of non-entrapped drug remaining in the aqueous supernatant. A Franz diffusion cell was used to monitor Stavudine release from the nanoparticles. The formulations CF1, CF2, EF2 and EF3 showed good drug release from the polymer. The percentage cumulative drug release after 12 hours was 75.54, 75.89, 78.86 and 76.42% respectively. However about 15% initial burst release was found at 1 hour in all formulations. EF2 released 78.86% of Stavudine 12 hours with a burst drug release nearly 14.86% of drug within the initial 1 hour. Formulations 4 out of 8showed good drug release from the polymer, the percentage cumulative drug release after 12 hours were in the range of 72-78 %. Among the four formulations EF 2 (1% Chitosan & 1.5 % EudragitS 100) showed maximum drug release in 12 hours diffusion study and good entrapment efficiency. In-vitro antiviral study revealed thatthe formulated nanoparticles were found to have good viral activity on viral cells in sustained manner.

This present review is progress in selected nanotechnology topics and some possible applications. This attempt mainly focused on Different Classes of Nanoparticles (Ceramic nanoparticles, Metallic particles, Carbon nanomaterials, Quantum dots) and Applications of Nanotechnology in Pharmaceuticals (Diagnosis, Pharmacology and Therapy, Molecular Diagnosis) and Nanoparticle Drug Delivery Systems and Toxicity of Nanoparticles. Nanoparticles mainly use aims to minimize drug degradation upon administration, prevent undesirable side effects, and increase drug bioavailability and the fraction of the drug accumulated in the pathological area.

Buccal administration of drug provides a convenient route of administration for both systemic and local drug actions. The preferred site for retentive oral transmucosal delivery systems and for sustained and controlled release delivery device is the buccal mucosa. Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs including peptides, proteins, polysaccharides and nucleic acids in great number possessing superior pharmacological efficacy with site specificity and devoid of untoward and toxic effects. However, the main impediment for the oral delivery of such drugs as potential therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Direct access to the systemic circulation through the internal jugular vein bypasses drug from the hepatic first pass metabolism leading to high bioavailability. The objective of this article is to review the developments in buccal adhesive drug delivery system as patches.

  The goal of present investigation highlights the formulation and evaluation of mucoadhesive buccal patches of Tramadol hydrochloride. The mucoadhesive buccal patches of Tramadol hydrochloride were prepared by solvent casting technique using various concentrations of Chitosan polymer. The formulated patches were evaluated for their physicochemical parameters like thickness, weight variation, surface pH, content uniformity, folding endurance swelling percentage studies and in vitro residence time. In vitro release studies were performed with pH 6.8 phosphate buffer solution. Good results were obtained both in physicochemical and in vitro studies. The films were exhibited controlled release more than six hours. The in-vitro release datas were fit to different equation and kinetic models to explain release profiles. The best mucoadhesive performance and matrix controlled release was exhibited by the formulation R6. The formulation was found be right and suitable candidate for the formulation of Tramadol HCL mucoadhesive buccal patches for therapeutic use. Key words: Tramadol HCL, Chitosan, Mucoadhesive buccal patches, PVP K-30.